April 2015 - The iCMLf Diagnosis and Testing Program offers seeding grants to hematology institutions in emerging economic regions. The aim of the program is to facilitate the diagnosis, testing and long-term disease monitoring of CML patients in emerging economic regions where it is not currently available.
Building on the success of the previous twenty-two projects awarded iCMLf grants, the Foundation will offer further funding in 2015 for up to 10 new proposals with a funding of $10,000.
Expressions of interest are welcome to melissa@cml-foundation.org.
Applications close on the 10th of July 2015.
April 2015 - The world of CML is ever evolving. New data, guidelines, research and expert opinions are constantly available. Come and follow the iCMLf on Facebook to keep up to date with CML news around the world, share information and find out more about the iCMLf programs that improve the outcomes for patients with CML globally.
Follow the Foundation here
March 2015 - The iCMLf is very pleased to announce a new prize recognizing outstanding contributions to overcome the challenge of treatingCML with limited resources. The Emerging Regions Support and Partnership (ERSAP) Prize will be awarded each year to an individual, or organisation that has made outstanding contributions to the treatment of CML in the emerging economic regions.
February 2015 - The annual Goldman Prize awarded by the iCMLf in honour of Professor John Goldman complements the iCMLf’s Rowley Prize as a clinical equivalent recognising outstanding lifetime contributions to the management of patients with CML. The iCMLf awards the 2015 Goldman Prize to Professor Michele Baccarani in recognition of his over forty years of dedication to clinical excellence in the management of CML.
February 2015 - The iCMLf Rowley Prize is designed to recognise persons who have made major contributions to the understanding of the biology of CML. In 2015 the Rowley Prize is awarded to Professor Richard Van Etten. This iCMLf award recognises Dr Van Etten’s groundbreaking research focusing on the development of new therapeutic strategies such as the tyrosine kinase inhibitors.
September 2014 - We are delighted to present the iCMLf Annual Report 2013/2014. It features the Foundation’s activities from Sept 1st 2013 to August 31st 2014.
Key outcomes from the iCMLf in the last 12 months include: